Galapagos NV (NASDAQ:GLPG) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. reduced its position in Galapagos NV (NASDAQ:GLPG - Free Report) by 12.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 70,413 shares of the biotechnology company's stock after selling 10,412 shares during the period. Ameriprise Financial Inc. owned about 0.11% of Galapagos worth $1,936,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Gilead Sciences Inc. purchased a new position in Galapagos during the fourth quarter worth approximately $461,727,000. Norges Bank acquired a new position in shares of Galapagos during the 4th quarter valued at $3,300,000. Finepoint Capital LP lifted its holdings in shares of Galapagos by 21.0% during the 4th quarter. Finepoint Capital LP now owns 674,762 shares of the biotechnology company's stock valued at $18,556,000 after acquiring an additional 117,000 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in Galapagos during the 4th quarter worth $726,000. Finally, XTX Topco Ltd boosted its position in Galapagos by 137.8% during the 4th quarter. XTX Topco Ltd now owns 19,833 shares of the biotechnology company's stock worth $545,000 after purchasing an additional 11,492 shares during the period. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Galapagos Stock Performance

Galapagos stock traded down $0.02 during midday trading on Wednesday, hitting $28.62. 98,466 shares of the stock were exchanged, compared to its average volume of 241,570. Galapagos NV has a 1 year low of $22.36 and a 1 year high of $31.23. The company has a 50 day moving average price of $26.24 and a two-hundred day moving average price of $26.03.

Galapagos (NASDAQ:GLPG - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The firm had revenue of $97.33 million during the quarter, compared to the consensus estimate of $72.22 million. On average, research analysts forecast that Galapagos NV will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wall Street Zen lowered Galapagos from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Morgan Stanley lowered Galapagos from an "equal weight" rating to an "underweight" rating and lowered their target price for the company from $31.00 to $22.00 in a research note on Friday, February 14th. Five analysts have rated the stock with a sell rating and four have assigned a hold rating to the company's stock. Based on data from MarketBeat, Galapagos currently has an average rating of "Reduce" and an average target price of $25.33.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.